CY-09

• Description :

  CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  NOD-like Receptor (NLR)

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/CY-09.html

• Purity :

  99.58

• Solubility :

  DMSO : ≥ 150 mg/mL|H2O : < 0.1 mg/mL

• Smiles :

  OC(C1=CC=C(/C=C2SC(N(CC3=CC=CC(C(F)(F)F)=C3)C\2=O)=S)C=C1)=O

• Molecular Formula :

  C19H12F3NO3S2

• Molecular Weight :

  423.43

• Precautions :

  H302

• References & Citations :

  [1]Jiang H, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017 Nov 6;214 (11) :3219-3238.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  NLRP3

• CAS Number :

  [1073612-91-5]